about
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline include...
Read More
2.08
-0.09
(-4.15%)
170.0K
XNAS Volume
XNAS 15 Jan, 2026 4:30 PM (EST)
Board Meeting
The latest board meeting for Opus Genetics Inc took place on 15 Jan 2026, for the purpose of J.P. Morgan 2026 Healthcare Conference
See details
Not Eligible
Expensive Valuation
Technically Bullish
Opus Genetics Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..